Ruxolitinib is a potent JAK1/2 inhibitor that was first approved for the treatment of myeloproliferative neoplasia (MPN) by the United States Food and Drug Administration (FDA) in 2011 and was subsequently used to investigate its anticancer effect in various solid tumors, including breast cancer [9,10,11,12]. Here, JAK1 is linked to breast cancer.